AMED Preclinical study

Not Applicable

• Conditions: mild cognitive impairment, preclinical Alzheimer disease; Dementia, Alzheimer's disease; F00, G30

• Registration Number: JPRN-jRCTs051180239
• Lead Sponsor: Shimada Hiroyuki

Brief Summary

Psychological tests, amyloid PET, MRI tests, and biochemical tests were performed on 40 registered subjects (25 males, 15 females, average age 74 years (65-83 years)). There were 3 preclinical ADs, 12 MCIs (7 early MCIs and 5 late MCIs), and 25 healthy individuals. These subjects were followed up every 12 months for up to 36 months.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-30
• Study Completion: 2020-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Subjects at the preclinical AD stage

Exclusion Criteria

Patients with dementia

Study & Design

• Study Type: Interventional
• Study Design: Not specified